Abstract
Tedizolid (TZD) is an oxazolidinone derivative which demonstrates bacteriostatic activity through inhibition of protein synthesis. We compared the efficacies of TZD and an earlier-generation oxazolidinone, linezolid (LZD), in an experimental murine model of bacteremia caused by two VRE strains (one each E. faecium and E. faecalis). LZD exhibited significantly better efficacy in terms of reduced VRE blood and target tissue densities than TZD in this model.
Highlights
Reviewed by: Gennaro De Pascale, Università Cattolica del Sacro Cuore, Italy Tianyu Zhang, Guangzhou Institutes of Biomedicine and Health (CAS), China
We compared the efficacies of TZD and an earlier-generation oxazolidinone, linezolid (LZD), in an experimental murine model of bacteremia caused by two Vancomycin-Resistant Enterococcal (VRE) strains
Used antimicrobial agents used to treat VRE bloodstream infections (VRE-BSI) infections, such as daptomycin, oritavancin, dalbavancin, quinupristin-dalfopristin, and tigecycline, each have a number of important side effects, both acutely and more long-term [2]
Summary
Reviewed by: Gennaro De Pascale, Università Cattolica del Sacro Cuore, Italy Tianyu Zhang, Guangzhou Institutes of Biomedicine and Health (CAS), China. We compared the efficacies of TZD and an earlier-generation oxazolidinone, linezolid (LZD), in an experimental murine model of bacteremia caused by two VRE strains (one each E. faecium and E. faecalis).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
